Positive Buy Rating for Rezolute Driven by Promising Phase 3 Study Results and Strong Efficacy Potential

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Rezolute. The associated price target remains the same with $12.00.

Yun Zhong has given his Buy rating due to a combination of factors that suggest a promising outlook for Rezolute’s stock. The Phase 3 sunRIZE study for ersodetug in patients with congenital hyperinsulinism (cHI) shows a strong potential for success, as it involves a patient demographic similar to the successful Phase 2b RIZE study. The inclusion of younger patients, who are in a more dynamic phase of the disease, could enhance the efficacy results in the Phase 3 trial.
Additionally, a higher percentage of Phase 3 participants have diazoxide non-responsive mutations, which may lead to a more pronounced efficacy of ersodetug compared to the standard of care. The interim data analysis has also reduced clinical risks, as the study continues without the need for an increased sample size. The primary endpoint of improved glycemic control has shown significant promise in previous trials, further supporting the potential success of the ongoing study. These factors combined have led Yun Zhong to maintain a positive outlook on Rezolute’s stock.